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How included are mental health service users in decisions about their 
medication? 
In this review I discuss four papers that concern decisions about medication in mental health 
services. Three papers mention a form of decision-making that should give service users equal power 
with the clinician - ͚shared decision-making͛ - and one uses an empowerment framework. Even so, I 
will suggest that the first paper (Angell and Bolden, 2015) shows how mental health service users 
can be disempowered in a meeting with a psychiatrist who appeaƌs to ďe takiŶg the seƌǀiĐe useƌ͛s 
concerns into account. The second paper (Delman, Clark, Eisen and Parker, 2015) suggests how 
young people in mental health care can begin to have more say as they get older but also shows 
what stands in the way of them doing so. The third paper (Mikesell, Bromley, Young, Vona and Zima, 
2016) shows how service users and professionals both have dilemmas about shared decision-
making, and seems to conclude that things cannot change much. The fourth paper (Morant, 
Kaminsky and Ramon, 2015) helps eǆplaiŶ ǁhǇ the ͚shared decision-ŵakiŶg͛ ŵodel does Ŷot tƌaŶsfeƌ 
easily from physical to mental health care. Professionals, they suggest, need to address the problem 
of disempowerment and stigmatising of service users in mental health care, as well as the wider 
organisational constraints, changing the organisation if necessary.  
What happens when a psychiatrist and a service user meet to talk about 
medication? 
AŶgell aŶd BoldeŶ ;ϮϬϭϱͿ desĐƌiďe ŵediĐatioŶ as ͞a ĐoƌŶeƌstoŶe of tƌeatŵeŶt͟ iŶ psǇĐhiatƌǇ ;p. ϰϰͿ. 
However, prescribing happens behind closed doors. It ǁas Ŷot Đleaƌ hoǁ ŵuĐh ͚shaƌed deĐisioŶ-
ŵakiŶg͛ ǁas happeŶiŶg, an approach recommended by Drake and Deegan (2009). Angell and Bolden 
(2015) suggest that in mental health there may be particular barriers to shared decision-making, 
such as when the service user had not wanted help from mental health services. Also, psychiatrists 
are assigned the task of risk management, which is often seen as ensuring that people are on 
medication or continue with it. This goes against the idea that it is up to the service user to decide. 
IŶdeed, the seƌǀiĐe useƌ͛s ƌesistaŶĐe to takiŶg ŵediĐatioŶ ŵaǇ ďe ǀieǁed as a sigŶ theǇ aƌe ͚ill͛ aŶd 
cannot make that decision. However, Angell and Bolden (2015) wondered if the long-term nature of 
soŵe seƌǀiĐe useƌs͛ ƌelatioŶships ǁith ŵeŶtal health seƌǀiĐes ŵight provide the opportunity for 
trusting relationships to develop between psychiatrists and service users, making it more possible 
that medication decision-making could be shared.  
Recording discussions between service user and psychiatrist 
Angell and Bolden (2015) used the research method of conversation analysis to look at recorded 
discussions between service user and psychiatrist to see how the medication decision was made. 
Conversation analysis enables us to see how people influence others in their conversations. So it is 
ideal for looking at how psychiatrists might persuade service users that they should take more or 
less of a medication. 
Angell and Bolden (2015) audio-recorded conversations between one psychiatrist and 36 different 
service users in one-to-one meetings to discuss their medication. The meeting was with the team 
psychiatrist in a multi-professional assertive community treatment service in an American city. 
Participants had been seen for an average of 12 years aŶd ŵost had a diagŶosis suĐh as ͚ďipolaƌ 
disoƌdeƌ͛ oƌ ͚sĐhizophƌeŶia͛.  
How a psychiatrist talked to service users 
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Angell and Bolden (2015) noted that the psychiatrist used two ways to persuade service users to 
agree to her suggestions regarding ŵediĐatioŶ. TheǇ Đalled these ͞ĐlieŶt-atteŶtiǀe͟ aŶd 
͞pƌofessioŶal authoƌitǇ͟ ;p. ϰϳͿ.  
͚Client attentiǀe͛ persuading: This was where the psychiatrist referred to the service useƌ͛s ƌepoƌted 
experiences, such as muscle tremor. The psychiatrist recognized this as a side effect, suggested it 
may be due to one of the two medications the service user was on, and recommended lowering one 
of them.  
Using ͚professional authority͛ to persuade: This was where the psychiatrist used either her 
knowledge from professional training, or for example blood tests. In the same meeting as described 
above, these tests enabled the psychiatrist to inform the service user that the level of lithium was 
low, and Depakote high, so she could suggest it was the Depakote that Đaused the seƌǀiĐe useƌ͛s 
tremor. The service user wished to reduce the lithium but the psychiatrist argued to keep it the 
same and lower the Depakote. The psychiatrist suggested that this would help with the tremor.  
In the article by Angell and Bolden (2015) there are seven short extracts from recorded 
conversations between a service user and the psychiatrist, and in all of them the psychiatrist by far 
speaks the most. This may be just because the authors chose sections that demonstrated how the 
psychiatrist justified her decision about medication. However, the sort of things the service user said 
iŶ these eǆtƌaĐts ǁeƌe thiŶgs like ͞What, eh͟, ͞OkaǇ͟, ͞Yeah͟, oƌ paƌtial seŶteŶĐes suĐh as ͞That 
doŶ͛t ŵeaŶ-͞. AŶgell aŶd BoldeŶ ;ϮϬϭϱͿ also ƌepoƌt that the psǇĐhiatƌist͛s deĐisioŶ ǁas ͞ƌaƌelǇ 
ĐhalleŶged ďǇ ĐlieŶts͟ ;p. ϱϰͿ.  
Occasionally a service user said more, but the psychiatrist seemed skilled at using service users͛ own 
experiences to persuade them of her decision. Angell and Bolden (2015) show how she sometimes 
used a seƌǀiĐe useƌ͛s oǁŶ ǁoƌds and her knowledge of the person to justify her decision. In one 
example she reminded a man of his negative experiences when he was on a lower dose of an 
aŶtipsǇĐhotiĐ ŵediĐatioŶ. UsiŶg soŵeoŶe͛s oǁŶ ǁoƌds ĐaŶ ďe peƌsuasiǀe ďeĐause it giǀes them the 
impression that they have been heard. In this instance the service user still disagreed with the 
psǇĐhiatƌist͛s ƌefusal to decrease his medication. The psychiatrist then predicted that his distressing 
experiences would come back if she did so. Angell and Bolden note that the psychiatrist spoke as if 
from an ͚expert͛ positioŶ, saǇiŶg thiŶgs like, ͞What ǁe fiŶd is usuallǇ…͟ (p. 52).  
Did the psychiatrist really involve service users? 
Angell and Bolden (2015) suggest that the psychiatrist was using persuasion in a caring way ͞to 
aĐhieǀe ĐoŶseŶsus͟ ;p. ϱϰͿ but they also remind us that she has the authority to decide about 
medication. The point about the psychiatrist͛s authoƌitǇ seeŵs keǇ, iŶ that it could be argued that 
the appaƌeŶt ͚consensus͛ was not real, since Angell and Bolden (2015) themselves point out that 
service users tended not to challenge the decision. In their study there was no evidence of 
alternatives to medication being suggested. Angell and Bolden (2015) concede that what they 
observed did not fit the vision of truly shared decision-making, but they suggest that perhaps such 
equal partnership is not easily possible because neither doctors nor patients are used to it. This does 
not strike me as a credible argument for maintaining an unequal status quo. I wonder what the 
service users would have said about their experience of these meetings with the psychiatrist, had 
they been asked. It may have felt disempowering when the psychiatrist used her knowledge of their 
history and what they had told her about their problems in order to justify why her decision was 
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ƌight. AƌguaďlǇ this is Ŷot good foƌ people͛s ŵeŶtal ǁell-being, since it could undermine any belief 
that they may be able to have their opinions about their own care taken seriously. 
What helps young people to share decisions about their medication? 
Delman et al. (2015) point out that many young people would like a more active part in decisions 
about treatment, and that not having this can make them less likely to use services. They highlight 
the teŶdeŶĐǇ of ǇouŶg people Ŷot to take ŵediĐatioŶs ďeĐause of uŶpleasaŶt ͚side effeĐts͛ suĐh as 
rapid weight gain. Delman et al. (2015) suggest that a theory called the Finfgeld empowerment 
model (Finfgeld, 2004) could be helpful. It has two levels, they tell us: choosing and negotiating. 
Choosing means the service user chooses between different options. Negotiating is more active, as it 
involves reaching a compromise if there is disagreement.  
Delman et al. (2015) describe an approach called ͚positive youth development͛, aimed at 
empowering young people to become more involved in decisions about their futures. The approach 
is based on the Finfgeld (2004) empowerment model, which recognises problems with the health 
care system itself, the seƌǀiĐe useƌ͛s leǀel of ĐoŶfideŶĐe aŶd ĐoŵŵitŵeŶt, aŶd hoǁ staff iŶ the 
system may help the service user to overcome these obstacles in order to take a more active role in 
decision-making. This leads, ideally, to service users feeling more empowered and to greater overall 
well-being.  
The study involved interviews with 24 young adults in mental health care in one American state 
about their views on how much they felt involved in decisions about their medication. They were 
between the ages of 18 and 30 and all had a diagnosis of a serious mental illness. Participants were 
only included in the study if they had asked their current psychiatrist for a specific medication or had 
disagreed with the psychiatrist and come to a negotiated decision. Most participants were white and 
two thirds were female.  
Delman et al. (2015) identified five things that young people said were helpful for their active 
participation in medication decisions, and three barriers to active participation.  
What made participating in medication decisions easier? 
Psychiatrist interest in serǀice users͛ ǁishes: Participants said that it helped when their psychiatrist 
listened and asked them for their opinion. In one case the psychiatrist agreed to go along with the 
paƌtiĐipaŶt͛s ǁish to Đoŵe off ŵediĐatioŶ, aŶd disĐussed a plaŶ to do it iŶ a safe ǁaǇ.  
Support from other staff: Staff of various services were helpful, for example those in a group home 
who offered to coach participants before they saw the psychiatrist, or attend the meeting and 
advocate for them. Most participants had meetings of only 15-20 minutes with the psychiatrist, and 
some said that it was helpful to inform the psychiatrist about what was on their mind through their 
counsellor or CBT therapist. 
Personal growth: Many participants felt that over time they had become more confident due to long 
experience with psychiatrists and therapists, although some thought this was due to the support and 
encouragement of other staff.  
Confidence: Some participants felt that their psychiatrist helped them to be more confident by 
inviting them to give their opinions, and some talked about gradually gaining knowledge through 
education or their own reading and searching the internet. Successful negotiation of medication 
decisions in itself also boosted confidence.  
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Psychiatrist availability: Some young people said that their psychiatrists made an effort to get more 
time for meetings with them, although this was not easy. Some psychiatrists made themselves 
available by phone between appointments, which the participants found very helpful. 
What made participation in decisions difficult? 
Lack of psychiatrist time: In contrast to the above, participants often talked about previous 
psychiatrists being less available. Participants had felt they did not listen or there was not enough 
tiŵe to eǆplaiŶ aďout uŶpleasaŶt ͚side effeĐts͛ aŶd that theǇ had to go aloŶg ǁith the psǇĐhiatƌist͛s 
wishes.   
Psychiatrist lack of interest: Again referring mainly to previous psychiatrists, participants felt that 
psychiatrists were in a rush, had no real interest in their longer-term goals, and that they ignored 
concerns about unpleasant effects of the medication. 
Serǀice users͛ loǁ self-efficacy: During their time in child and adolescent mental health care, 
participants had the experience of their parents and psychiatrist making decisions. They were not 
aware of their right to refuse medication or to change their psychiatrist, and had not developed any 
sense of being able to negotiate in decisions. Some reported being glad they now had more 
confidence to do these things. 
How can people be more included in their medication decisions? 
Although Delman et al. (2015) demonstrate that psychiatrist behaviour is sometimes a barrier to 
young people having a say in their medication, they also point out organisational constraints that 
make it difficult for psychiatrists to give people more time. PsǇĐhiatƌists͛ traditional tendency of 
paternalism is also a problem, Delman et al. (2015) suggest, making them reluctant to trust the 
judgment of service users who have a diagnosis of serious mental illness. However, Delman et al. 
(2015) have demonstrated conditions under which some young adults can have more say in 
decisions about medication. They suggest that psychiatrists need training in how to invite people to 
take a more active role, and how to negotiate compromises when there is disagreement. They see a 
role for peer support workers in coaching service users before they meet with their psychiatrist. 
They suggest parents may welcome gƌeateƌ iŶǀolǀeŵeŶt iŶ suppoƌtiŶg the ǇouŶg peƌsoŶ͛s 
development and more active decision-making.  
What do professionals and service users think about how medication 
decisions are made? 
Mikesell et al. (2016) interviewed both service users and professionals about how medication 
deĐisioŶs ǁeƌe ŵade. TheǇ eǆplaiŶ the ͚shaƌed deĐisioŶ-ŵakiŶg͛ ŵodel as haǀiŶg thƌee paƌts:  
 Unbiased information 
 Collaboration 
 Mutual respect 
Mikesell et al. (2016) focus on the information part of decision-making. The participants in this 
American study were two administrators, three team leaders (one to one interviews), 25 clinicians 
who were case managers (focus groups), 14 service users and 6 family members (focus groups). They 
were all connected with two services in California. Service users tended not to have health insurance 
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and the clinics were publicly funded. The researchers asked participants whether they thought 
service users had difficulty deciding about medication, and whether they felt that a decision-aid tool 
could help. The decision tool provided information about different medications, iŶĐludiŶg ͚side 
effeĐts͛, aŶd aiŵed to help people Đoŵe to theiƌ deĐisioŶ. The professionals who prescribed 
medication were all psychiatrists but none took part in the study. Service users all had a diagnosis of 
͞eitheƌ a psǇĐhotiĐ oƌ ŵood disoƌdeƌ͟ ;Mikesell et al., ϮϬϭϲ, p. ϳϬ9Ϳ. Fouƌ of the ϭϰ seƌǀiĐe useƌs 
were white, and eight were men.  
Mikesell et al. (2016) reported three themes: being client-centred, exchanging information, and a 
theme of expertise. Regarding the need to be client-centred, all participants seemed keen that 
service users were involved and empowered in decision-making about medication. Service users felt 
that the decision tool would help them in this. Clinicians stated that there was no coercion and that 
service users had the right of choice. However, when it came to how choice could happen, things 
became more complicated.  
Double messages about information given to service users 
Information should be clear and unbiased: Both professionals and service users thought that 
information given to service users about medication should be full and nothing should be held back. 
Professionals thought they should help seƌǀiĐe useƌs to tell psǇĐhiatƌists aďout ͚side effeĐts͛ aŶd 
support them to negotiate about decisions. They expressed concern that service users did not 
always have full information – for example not knowing that their weight gain was likely to be due to 
having been on a certain medication for some years. They suggested other service users could 
provide information from their experiences. Service users felt that finding out more about 
ŵediĐatioŶs aŶd theiƌ ͚side effeĐts͛ Đould ďe eŵpoǁeƌiŶg. 
Problems about communicating information: In contrast to their assertions that they gave full and 
Đleaƌ iŶfoƌŵatioŶ aŶd that theƌe ǁeƌe ͞Ŷo head gaŵes͟ ;Mikesell et al., ϮϬϭϲ, p. ϳϭϭͿ, professionals 
also said that information about side effects was concealed. They would not want to tell a young 
person or their parent that they could gain weight rapidly on starting a medication. Mikesell et al., 
2016) describe this concealment as a seŶse of ͞theƌapeutiĐ oďligatioŶ͟ ;p. ϳϭϭͿ. Professionals 
suggested that the decision tool could be confusing because it gave too much information, and some 
service users took a similar view, or thought they might focus only on the negative things such as the 
͚side effeĐts͛. EǀeŶ so, ͚side effeĐts͛ ŵaǇ ƌeduĐe theiƌ ĐoŵpliaŶĐe, service users suggested, but they 
might not tell the psychiatrist for fear of disapproval.  
Mutual ŵistrust about ͚expert͛ kŶowledge 
What service users know: There was general recognition that service users know about their 
͚sǇŵptoŵs͛ aŶd hoǁ theiƌ ŵediĐatioŶ affects them, and it was helpful for professionals to listen to 
this. However, service users tended to express doubt that they could make sensible decisions when 
they were in crisis, and some also felt they could not trust themselves to know when they were well. 
One professional viewed service users as unable to do what most people would do in terms of 
finding information or knowing their rights, but did not appear to advocate empowerment.  
What professionals know: Whilst sometimes both professionals and service users suggested that 
seƌǀiĐe useƌs plaĐed too ŵuĐh faith iŶ pƌofessioŶals͛ kŶoǁledge, seƌǀiĐe useƌs also iŶdiĐated that it 
could be difficult to question their authority. A professional acknowledged that a peer support 
worker had been most helpful in resolving one situation they had encountered. Service users would 
sometimes look up information on the internet or someone else did, for example a spouse, after the 
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meeting with a psychiatrist, and then they made the decision whether to take the medication. 
SeƌǀiĐe useƌs ǁeƌe Ŷot iŵpƌessed ďǇ the appaƌeŶt ͞tƌial aŶd eƌƌoƌ͟ ŵode of ǁoƌkiŶg out ǁhiĐh 
medication would be best, or which combination. However, it was difficult to do anything other than 
go along with the doctor when they felt dependent on them.  
Losing the big picture? 
Mikesell et al. (2016) wonder if the shared decision-making model, when applied in mental health, 
should allow for the professional to persuade service users to take medication. However, this 
overlooks the ƌeal issue of haƌŵful ͚side effeĐts͛ that may take a toll on physical health over time. 
Risk management appears to be seen only in narrow terms of current mental health ͚sǇŵptoŵs͛, 
and not at all in terms of long-term physical health, even to the extent that risks to physical health 
may be concealed from service users. Mikesell et al. (2016) note that professionals work in contexts 
where alternative treatment may not be available, limiting the options they can offer. Indeed their 
role is partly to ensure compliance, which is incompatible with fully shared decision-making. Mikesell 
et al. (2016) cite Makoul and Clayman (2006) in suggesting that unbiased information may not 
always be advisable in mental health, although it ĐaŶ ďe aŶ ͚ideal͛ to aim for when circumstances 
allow. This leaves open the question of when the professional will deem the service user to be 
capable of shared decision-making, and this may continue to be over-ruled by the focus on 
͚sǇŵptoŵs͛ aŶd laĐk of a ǁideƌ peƌspeĐtiǀe oŶ seƌǀiĐe useƌs͛ liǀes aŶd goals. 
Can shared decisions about medication become routine? A UK perspective 
Morant et al. (2015) suggest the need to take a wider perspective, looking at the organisational 
constraints on professionals rather than just the doctor-patient encounter. They note that shared 
decision-making is promoted in UK health policy but that in mental health it seems slow to take hold, 
in keeping with reports from America. They point out that service users have reported both benefits 
of medication and unpleasant and harmful effects. Harms include ͞ǁeight gaiŶ, dƌoǁsiŶess aŶd 
ŵeŶtal ĐloudiŶg, ƌeduĐed liďido, iŶǀoluŶtaƌǇ ŵoǀeŵeŶts aŶd diaďetes͟ ;p. ϯͿ. These problems can 
be as difficult as the original mental health difficulties, and explain why there is a high rate of non-
compliance with prescribed psychiatric medication, Morant et al. (2015) suggest. Psychiatrists, they 
saǇ, Ŷeed to ƌeĐogŶise people͛s aďilitǇ to self-manage their medication. 
There is a problem of over-prescribing of medication, say Morant et al. (2015), with failure to reduce 
medication after a crisis is over, and prescribing more than one medication at a time, which 
increases the negative effects. The helpfulness of antipsychotic medication, they suggest, has been 
exaggerated (Moncrieff, 2009; 2013). Furthermore, Morant et al. (2015) cite studies suggesting that 
people may not need much medication if they have the right support (Romme, Escher, Dillon, 
Corstens and Morris, 2009; Seikkula, Alkare and Altonen, 2011). Yet the problems persist, with 
psychiatrists not really involving people in medication decisions.  
Morant et al. (2015) present a modified theory of shared decision-making that includes the wider 
mental health system, the GP, carers, and support forums and social networks. It also incorporates 
the long-term relationships between the service user and the service or a psychiatrist.  
Professionals can change what they do 
There is a need, suggest Morant et al. (2015) for professionals to be ready to discuss openly the 
limits to shared decision-making in mental health care, such as the organisational concern with 
managing risk. Morant et al. (2015) suggest that over time, as a therapeutic relationship develops 
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between a professional and a service user, it may become more possible for the professional to use 
a coaching approach, encouraging service users to talk about their life and long-term goals and take 
a more active part in decisions. However, they also note the possibility for service users to feel 
progressively more disempowered over time if professionals continually use coercion such as depot. 
MoƌaŶt et al. ;ϮϬϭϱͿ suggest faŵilǇ Đaƌeƌs aŶd ŵeŵďeƌs of iŶteƌŶet foƌuŵs oƌ people͛s ǁideƌ soĐial 
Ŷetǁoƌk ŵaǇ ďe aďle to suppoƌt seƌǀiĐe useƌs͛ aĐtiǀe deĐisioŶ-making, and that this should be 
encouraged. Other mental health staff can also support and coach people to ask for what they want, 
but they may need training to increase their confidence in their understanding of medication. GPs 
ŵaǇ ďe eƋuallǇ ƌeluĐtaŶt to adǀise, leaǀiŶg it to the ͚eǆpeƌt͛ psǇĐhiatƌist.  
Changing the culture 
In relation to the culture of mental health care, Morant et al. (2015) suggest that the tendency to 
see mental health problems as mainly medical and requiring medication needs to be changed 
because it stops professionals seeing other causes and other solutions. Professionals, they suggest, 
also teŶd to ďe too pessiŵistiĐ aďout people͛s loŶg-term future, and fearful of reducing medication 
iŶ Đase of ƌelapse, ǁhile ŵissiŶg the ƌisk that ŵediĐatioŶ poses to people͛s loŶg-term physical health. 
They also have a ƌole of keepiŶg soĐietǇ safe ďǇ ĐoŶtƌolliŶg people͛s ďehaǀiouƌ, saǇ MoƌaŶt et al. 
(2015), and they are influenced by the pharmaceutical industry. All these forces need to be looked at 
if there is any hope of changing things. 
Training 
The issue of serviĐe useƌs͛ oǁŶ wish for less autonomy when in crisis also needs to be 
acknowledged, say Morant et al. (2015). However, they suggest that coercion and control spill over 
too much into times when service users are able to be actively involved in decisions. Psychiatrists 
may need reassurance that it is not time-consuming to involve service users in decisions, say Morant 
et al. (2015). There was one randomised controlled trial of shared decision-making in inpatient 
settings, say Morant et al. (2015), but staff did not continue using it after the end of the trial. They 
suggest that training in shared decision-making should be available both to care-coordinators and 
service users themselves. Discussions could be structured around computer information and 
decision tools. Service users could meet with a peer worker before meeting the psychiatrist, so that 
the psychiatrist will not need to spend more time with the service user.  
More research might help things change 
Morant et al. (2015) suggest there is more research needed, especially on the role of peers, other 
staff, and family members, and on situations where the service user is in crisis. The things in the 
wider system that help or hinder shared decision-making need to be studied. Staff other than 
psychiatrists need greater knowledge about medication, and all need to learn more about how 
service users can and do successfully manage their medication and use other resources. 
Professionals may think they use shared decision-making while service users do not perceive it that 
way, say Morant et al. (2015). A gradual reduction of medication with support is better than the 
service user unilaterally deciding to stop medication because they have lost faith in the 
pƌofessioŶal͛s ability to listen, they suggest. Service reconfiguration may be needed to truly support 
shared decisions. Using their expanded model of shared decision-making may help make this 
possible, Morant et al. (2015) suggest.  
Conclusions 
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There is growing research suggesting that the positive effects of psychiatric drugs have been 
exaggerated and that they have long-term harmful effects. It seems imperative, therefore, as Drake 
and Deegan (2009) suggested, that decisions about medication are shared and not imposed on 
service users. Risk management should include the risk of long-term harm to physical health and 
survival. Alternatives to medication need to be more widely available, especially psychological 
therapies. The social deprivation that causes people on-going stress needs to be addressed. Mental 
distress has come to be viewed as a medical problem when it is in fact a social problem. It needs 
psychological and social solutions, not drugs (British Psychological Society, 2014). The articles 
discussed here demonstrate that the mind-set of viewing mental distress as a medical problem and 
seeking to impose narrow medical solutions needs to shift a lot more. The study by Delman et al. 
(2015) seemed a little more hopeful in that an empowerment model seemed to help young people 
to develop more confidence to negotiate decisions with their psychiatrist, although these young 
people were selected on the basis that they had done this. It is impossible to know how many other 
young adults still felt deeply disempowered in the surrounding mental health system. Morant et al. 
(2015), writing in a UK context, seemed to have some promising suggestions for changing the culture 
and organisation of mental health services. However they do not underestimate the barriers to 
change, which are political and social, and not just about funding.  
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